February may be the shortest month, but we got an extra day this year and that left plenty of time for personnel announcements in the pharma world. Read on for

As the global obesity epidemic continues to escalate, the development of effective obesity management solutions has become a front and centre topic in the life sciences sector. With over 650

To mark upcoming Rare Disease Day, pharmaphorum asked a panel of experts to give their thoughts on the opportunities and challenges facing developers of rare disease therapies in 2024. The

U.K.-based Poolbeg Pharma is taking a different approach with its POLB 001, a small molecule immunomodulator that has already shown promise in a lipopolysaccharide (LPS) human challenge trial. A human challenge

Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS)

Cathal Friel, co-founder, substantial shareholder, and currently non-executive chairman of London-listed Poolbeg Pharma (AIM: POLB), is assuming the role of executive chairman at the company effective immediately. As executive chair

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively

Businessman Cathal Friel has become executive chairman of Poolbeg Pharma, the same job he had at Open Orphan (now hVivo) as that firm was developed. Mr Friel, a co-founder and